Seeking Alpha
25 Feb 2026, 15:03 UTC · 33w ago
Oruka Therapeutics: A Potential Future Psoriasis Play
Impact · against what's priced in
ORKA is a high-risk, long-duration play with a potential best-in-class dosing advantage, though monetization is years away. ABBV faces a distant competitive threat in the psoriasis market, though it remains the current gold standard.
- ORKA+0.60
No priced-in read yet
- In context
ORKA-001's Phase 1 half-life being four times longer than Skyrizi creates a significant competitive advantage in dosing frequency, though this is balanced by the long wait for revenue until 2031.
Read from the article alone
Top 1 mover · tap to explore
